[Clinical experiences with a new orally effective antiarrhythmic agent (Aprindin)].
D000284:Administration, Oral; D000814:Aniline Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004048:Diethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004341:Drug Evaluation; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use*; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced
D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents; D004048:Diethylamines; D007189:Indans; D007192:Indenes
Klinische Erfahrungen mit einem neuen oral wirksamen Antiarrhythmikum (Aprindin)